Cafepharma Today

May 15 2025 - FDA approves Amneal's self-administered migraine treatment
FDA approves Amneal's self-administered migraine treatment
VC firm reveals plan for 30K-square-foot biotech incubator space in New Jersey
Philips taps Nvidia to build AI model for MRI
FDA delays decision on Biohaven's rare disease drug filing, plans adcomm
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease
Yahoo/Globe Newswire
Wednesday, June 18, 2014 - 8:36am
tags:
PRX-112, Protalix BioTherapeutics, Gaucher disease
Expecting hostile suitors, Shire brings in reinforcements
Fierce Pharma
Wednesday, June 18, 2014 - 5:31am
tags:
Shire, M&A, Bristol-Myers Squibb, Amgen, AbbVie, Gilead Sciences, Biogen Idec
Analyst: GlaxoSmithKline's Tykerb dead in the water after breast cancer failure
Fierce Pharma
Wednesday, June 18, 2014 - 4:29am
tags:
GSK, Tykerb, breast cancer
IPO Preview: ZS Pharma
Seeking Alpha
Wednesday, June 18, 2014 - 4:25am
tags:
IPOs, ZS Pharma
IPO Preview: Parnell Pharmaceuticals Holdings
Seeking Alpha
Wednesday, June 18, 2014 - 4:24am
tags:
Parnell Pharmaceuticals, IPOs, animal health
Cipla’s Drug Pipeline Makes It $10 Billion Prey: Real M&A
Bloomberg
Wednesday, June 18, 2014 - 4:23am
tags:
Cipla, M&A, India, Mylan, Teva Pharmaceuticals
Pfizer signs cancer immunotherapy deal with France's Cellectis
Yahoo/Reuters
Wednesday, June 18, 2014 - 4:22am
tags:
Pfizer, France, Cellectis, cancer immunotherapy
Responding to critics, Valeant CEO says company can grow organically
Marketwatch
Wednesday, June 18, 2014 - 4:21am
tags:
Valeant Pharmaceuticals, Allergan, M&A, J. Michael Pearson
Time Isn’t on Valeant’s Side in Allergan Bid
Barron's
Wednesday, June 18, 2014 - 4:20am
tags:
Valeant Pharmaceuticals, M&A, Allergan
Valeant Readies Hostile Exchange Offer for Allergan
TheStreet.com
Tuesday, June 17, 2014 - 7:07pm
tags:
hostile takeover, Valeant Pharmaceuticals, Allergan, M&A
Is This Gilead's Worst Nightmare?
Motley Fool
Tuesday, June 17, 2014 - 7:00pm
tags:
Gilead Sciences, Sovaldi, hepatitis C, Enanta Pharmaceuticals, AbbVie
Major pharmaceutical groups may be too big to succeed
FT.com
Tuesday, June 17, 2014 - 6:54pm
tags:
M&A, Pfizer, AstraZeneca
Glaxo's Promacta Holds Promise
Yahoo/Zacks.com
Tuesday, June 17, 2014 - 6:50pm
tags:
GSK, Promacta, chronic immune thrombocytopenic purpura
[video] Medical Marijuana Industry Revenue Could Reach $8.4 Billion
TheStreet.com
Tuesday, June 17, 2014 - 6:14pm
tags:
Medical Marijuana
Merck drops development of Endocyte cancer drug
Yahoo/AP
Tuesday, June 17, 2014 - 6:13pm
tags:
ovarian cancer, Merck, Endocyte, vintafolide
Purdue Pharma Reorganizes and Cuts One-Third of R&D
WSJ Online
Tuesday, June 17, 2014 - 4:39pm
tags:
R&D, Purdue Pharma, layoffs
GW Pharma Up On Positive Data For Epilepsy Drug
Investors.com
Tuesday, June 17, 2014 - 4:37pm
tags:
epilepsy, GW Pharma, Epidiolex
Novartis, Pfizer seek U.S. approval of meningitis vaccines
Yahoo/Reuters
Tuesday, June 17, 2014 - 4:34pm
tags:
Novartis, Pfizer, vaccines, FDA, meningitis, bivalent rLP2086, Bexsero
Indian Firm Develops Inexpensive Vaccine for Battle With Cholera
WSJ
Tuesday, June 17, 2014 - 8:35am
tags:
Hilleman Laboratories, vaccines, cholera
FIbrocell Science Announces Exclusive Technology License Agreements with UCLA to Advance the Development of Personalized Cell Therapies
Motley Fool
Tuesday, June 17, 2014 - 8:28am
tags:
Fibrocell Science

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.